Source: www.novartis.com
Novartis announced the approval of Xolair (omalizumab) by the European Commission. Xolair is a prefilled syringe that patients with severe allergic asthma and chronic spontaneous urticaria (CSU) can use to administer their own treatment.
Xolair targets immunoglobulin E, and is the first and only biologic to be approved in the European Union, Iceland, Norway, and Liechtenstein. This drug can be used for the treatment of severe allergic asthma in patients 6 years of age and older. It can also be used to help treat chronic spontaneous urticaria in patients 12 years of age and older who continue to have hives that are not controlled by H1 antihistamines.
